HC Wainwright & Co. Maintains Buy on Krystal Biotech, Raises Price Target to $221
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Krystal Biotech and increased the price target from $200 to $221, indicating confidence in the company's future performance.
August 28, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Krystal Biotech and increased the price target from $200 to $221, suggesting a positive outlook for the company's stock.
The increase in the price target from $200 to $221 by a reputable analyst firm like HC Wainwright & Co. suggests a strong positive outlook for Krystal Biotech. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100